Efficacy of ondansentron treatment for acute emesis with different dosing schedules 8 vs 32 mg. A randomized study

Journal of Experimental and Clinical Cancer Research

Volumn 20, Issue 1, 2001, Pages 29-34

  Tsavaris, N ^a   Kosmas, Ch ^a   Vadiaka, M ^a   Kontos, A ^a   Katsorida, M ^a   Dimitrakopoulos, A ^a   Zerai, A ^a   Koufos, Ch ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Cisplatin; Nausea; Non small lung cancer; Ondansentron; Vomiting

Indexed keywords

CISPLATIN; DEXAMETHASONE; ETOPOSIDE; MITOMYCIN; ONDANSETRON; VINBLASTINE;

ADULT; AGED; ARTICLE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DOSE CALCULATION; DRUG EFFICACY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PATIENT SELECTION; PRIORITY JOURNAL; SCORING SYSTEM; TREATMENT INDICATION;

AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MITOMYCIN; NAUSEA; ONDANSETRON; VINBLASTINE; VOMITING;

EID: 0035020156     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Stratified, randomized, double-blind comparison of intravenous ondansentron administered as a multiple dose regimen versus two single dose regimens in the prevention of cisplatin induced nausea and vomiting
2. Cisplatin and emesis: Aspects of treatment and a new trial for delayed emesis using oral dexamethasone plus ondansentron beginning 16 hours after cisplatin
3. Progress in the control of acute and delayed emesis induced by cisplatin
4. Comparison of the antiemetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose in acute cisplatin-induced emesis
5. Comparison of two different doses of ondansentron plus daxamethason in the prophylaxis of cisplatin-induced emesis
6. Approaches to management of emesis
7. Comparison of Ondansentron(GR 38032F) vs Ondansentron plus Alprazolam as antiemetic prophylaxis during cisplatin containing chemotherapy
8. Comparison of Ondansentron (GR 38032F) vs Ondansentron plus Methylprednizolone as antiemetic prophylaxis during Cisplatin containing chemotherapy
9. The influence of Ondansentron and Metoclopramide on electrolyte inbalance in patients with nausea and vomiting receiving cisplatin based chemotherapy
10. A randomized comparative study of antiemetic prophylaxis with ondansentron in a single 32 mg loading dose versus 8 mg every 6 hrs in patients undergoing cisplatin based chemotherapy
11. Single 8 mg dose of oral ondansentron failed to prevent FAC chemotherapy - Induced acute nausea and vomiting
12. Controlling cancer chemotherapy - Induced emesis: An update
13. Phase II trials of the serotonin antagonists GR 38032F for the control of vomiting caused by cisplatin
14. The use of ondansentron in patients receiving multiple day cisplatin regimens
15. Control of acute cisplatin-induced emesis over repeated courses of chemotherapy